Xaluritamig clinical trials
Also written AMG 509.
How each study uses xaluritamig is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the xaluritamig studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 1
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test xaluritamig.
- Feb 2027Evaluation of Neoadjuvant Xaluritamig in Localized Prostate CancerPhase 1 · Amgen
- Mar 2027Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate CancerPhase 1 · Amgen
Studies
Open first, then newest update. How each study uses xaluritamig is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)RecruitingPhase 1AmgenNCT07297979Written as Xaluritamig
- A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerRecruitingPhase 3AmgenNCT07213674Written as Xaluritamig
- Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate CancerRecruitingPhase 1AmgenNCT07493512Written as Xaluritamig
- Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate CancerRecruitingPhase 1AmgenNCT04221542Written as AMG 509
- LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide TetraxetanNot yet recruitingPhase 2Thomas Jefferson UniversityNCT07737925Written as Xaluritamig
- Evaluation of Neoadjuvant Xaluritamig in Localized Prostate CancerRecruitingPhase 1AmgenNCT06613100Written as Xaluritamig
- Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate CancerActive, not recruitingPhase 1AmgenNCT06555796Written as Xaluritamig
- Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)Active, not recruitingPhase 3AmgenNCT06691984Written as Xaluritamig
Given beside what is tested · 1 — xaluritamig is usual care or a partner of the new treatment
Codes
What other systems call xaluritamig · ClinicalTrials.gg INT017472
- UNII (FDA) ODG03B9M4UXALURITAMIGOne source FDA
- NCI Thesaurus C168580XaluritamigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | ODG03B9M4U | XALURITAMIG | One source FDA |
| NCI Thesaurus | C168580 | Xaluritamig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.